These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33462831)

  • 1. Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology.
    Li TR; Chatterjee M; Lala M; Abraham AK; Freshwater T; Jain L; Sinha V; de Alwis DP; Mayawala K
    Clin Pharmacol Ther; 2021 Jul; 110(1):200-209. PubMed ID: 33462831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
    Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
    Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
    Smart K; Bröske AM; Rüttinger D; Mueller C; Phipps A; Walz AC; Ries C; Baehner M; Cannarile M; Meneses-Lorente G
    Clin Pharmacol Ther; 2020 Sep; 108(3):616-624. PubMed ID: 32575160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.
    Novakovic AM; Wilkins JJ; Dai H; Wade JR; Neuteboom B; Brar S; Bello CL; Girard P; Khandelwal A
    Clin Pharmacol Ther; 2020 Mar; 107(3):588-596. PubMed ID: 31553054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
    Ahamadi M; Freshwater T; Prohn M; Li CH; de Alwis DP; de Greef R; Elassaiss-Schaap J; Kondic A; Stone JA
    CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):49-57. PubMed ID: 27863186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects.
    Dai HI; Vugmeyster Y; Mangal N
    Clin Pharmacol Ther; 2020 Dec; 108(6):1156-1170. PubMed ID: 32557643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of pembrolizumab in patients with advanced tumors.
    van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T
    J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial.
    Xiang H; Liu L; Gao Y; Ahene A; Macal M; Hsu AW; Dreiling L; Collins H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):595-606. PubMed ID: 32965540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.
    Tinker AV; Hirte HW; Provencher D; Butler M; Ritter H; Tu D; Azim HA; Paralejas P; Grenier N; Hahn SA; Ramsahai J; Seymour L
    Clin Cancer Res; 2019 Oct; 25(20):6052-6060. PubMed ID: 31308062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
    Peer CJ; Heiss BL; Goldstein DA; Goodell JC; Figg WD; Ratain MJ
    J Clin Pharmacol; 2022 Apr; 62(4):532-540. PubMed ID: 34648187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics/pharmacodynamics model.
    Wang J; Giragossian C; Hansel S
    Eur J Pharm Biopharm; 2021 Nov; 168():110-121. PubMed ID: 34478854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.
    Elassaiss-Schaap J; Rossenu S; Lindauer A; Kang SP; de Greef R; Sachs JR; de Alwis DP
    CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):21-28. PubMed ID: 27863143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial).
    Kawazoe A; Kuboki Y; Shinozaki E; Hara H; Nishina T; Komatsu Y; Yuki S; Wakabayashi M; Nomura S; Sato A; Kuwata T; Kawazu M; Mano H; Togashi Y; Nishikawa H; Yoshino T
    Clin Cancer Res; 2020 Nov; 26(22):5887-5894. PubMed ID: 32694160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
    Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biophysical and Immunological Characterization and
    Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
    Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.